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a  b  s  t  r  a  c  t
Marie Sklodowska-Curie, an extraordinary woman, a Polish scientist who lived and worked
in  France, led to the development of nuclear energy and the treatment of cancer. She was the
laureate of two Nobel Prizes, the first woman in Europe who obtained the degree of Doctor of
Science and opened the way for women to enter fields which had been previously reserved
for  men only. As a result of her determination and her love of freedom, she has become an
icon  for many female scientists active in radiation sciences. They are successors of Maria
Curie and without the results of their work, improvement in radiation oncology will not be
possible. Many of them shared some elements of Maria Curie’s biography, like high ethical
and moral standards, passionate dedication to work, strong family values, and scientific
collaboration with their husbands. The significance of Tikvah Alper, Alma Howard, Shirley
Hornsey, Juliana Denekamp, Helen Evans, Eleanor Blakely, Elizabeth L. Travis, Fiona Stewart,
Andree Dutreix, Catharine West, Peggy Olive, Ingela Turesson, Penny Jeggo, Irena Szumiel,
Eleonor Blakely, Sara Rockwell and Carmel Mothersill contribution to radiation oncology is
presented. All the above mentioned ladies made significant contribution to the developmentof  radiotherapy (RT) and more efficient cancer treatment. Due to their studies, new schedules
of  RT and new types of ionizing radiation have been applied, lowering the incidence of
normal tissue toxicity. Their achievements herald a future of personalized medicine.
©  2015 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
demonstrated that radiation is a powerful tool with a wide
range of potential applications, which include a range of diag-“Therapy should be permanently backed up by scientific
research without which no progress is possible. Moreover,
the search for pure knowledge is one of the important
needs of mankind. . .”.Marie Curie (From Marie Curie’s speech made at the
opening of the Radium Institute in Warsaw, May 1932)
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nostic and therapeutic medical procedures. Marie Curie has
left a great deal to the world. Her work led to the development
























































land, high ethical and moral  standards, passionate dedicationreports of practical oncology and 
f nuclear energy and radiotherapy (RT) for the treatment of
ancer. She also improved the image  of science. Marie Curie,
he first woman in Europe to obtain the degree of Doctor of
cience, the first female professor at Sorbonne, opened the
ay for women to enter fields which had been previously
eserved for men. As a result of her determination and her
ove of freedom, she has become a role model for 20th cen-
ury female radiobiologists presented here and who continue
arie Curie’s legacy development of radiotherapy. It is there-
ore worthwhile to highlight her many  achievements and her
ersonality, which make her a role model for scientists today.
Marie Sklodowska-Curie was born in Warsaw, Poland, on
 November 1867, and because women were not allowed to
tudy at Polish universities she left the country to continue
er education in France. She won her licenciate in physics at
he Faculty des Science at Sorbonne already in 1893, and in
athematics a year later.
In 1894 she was introduced to Pierre Curie (1859–1906), a
rench physicist. Soon after, Pierre realized he had found a
atching soul and wrote to Marie: “How wonderful would it
e if we  could spend our lives together, following our ideas.
our patriotic ideas, and our common ideas of humanity and
cientific research”. Their marriage (25 July 1895) marked the
eginning of a remarkable partnership. They worked in an old
ooden shed, with a skylight roof, a former prosectorium of
 medical school. Pierre concentrated on physics, Marie on
hemistry, she was mainly occupied with isolating uranium
alts from tones of ores. Marie published her first research
aper on magnetism of tempered steel.1 She presented the
esults of her solo work on Becquerel’s rays and suggested the
xistence of a new element. Pierre Curie joined her research
ork in March 1898. The Curies’ investigation of the radi-
tion in uranium ore led, in 1898, to the discovery of two
ighly radioactive new chemical elements, polonium (named
y Marie in honor of Poland) and radium.2,3
Marie struggled to obtain pure radium in the metallic state.
hen this was achieved, the Curies idealistically resigned
rom the right to patent the radium isolation method. They
ublished all the results of their studies along with the
etailed manufacturing processes and offered free informa-
ion on the subject. Marie Curie wrote: “Radium is a chemical
lement, a property of all humans”.
In 1903, Marie Sklodowska-Curie received both her doctoral
egree for her studies on radioactive substances and, together
ith her husband and Henri Becquerel, the Nobel Prize in
hysics. But the prize nearly remained in the male company.
nly Pierre Curie and H. Becquerel were initially nominated
s candidates, while Marie’s contribution was ignored. Marie’s
ole was finally acknowledged after Pierre Curie wrote to the
ominating committee saying that either he and his wife were
onored together or he would resign from his candidacy. This
s the example of the Curies’ supportive relationship.
After Pierre Curie’s sudden death in an accident on 19 April
906, Marie was appointed to succeed him as head of the
hysics department at the Sorbonne.
In 1911, she received the Nobel Prize in chemistry for her
ork on the isolation of metallic radium. In the same year sheook part in the Solway Conference, where she was the only
oman amongst men-scientists that included Niels Bohr, Max
lanck and Albert Einstein.therapy 2 1 ( 2 0 1 6 ) 250–258 251
Due to Marie Sklodowska-Curie’s efforts, the Radium Inti-
tute in Paris (Pierre’s dream) was founded in 1912. In 1914,
Marie became head of the Curies Pavilion and worked there
until her death. The social impact of Marie Curie’s work can
be seen during the World War I, when she organized a mobile
radiographic unit and took it to the battlefront where she
frequently operated it herself examining the wounded and
training radiographic assistants. At a rough estimate, as a
result of Marie Curie’s involvement more  than 150 radiolo-
gists were trained at her courses; over 200 X-ray laboratories
(including 20 mobile units) were organized for military hos-
pitals, and more  than a million soldiers were helped by
radiography before surgery.
In 1921 and 1929, Marie Curie made two triumphant jour-
neys to the United States. During the first trip, the President
of the United States, Warren Harding, presented her with a
gram of radium that had been bought by American women.
She donated it to the Radium Institute in Paris. From the sec-
ond trip to the United States (1929) she brought money to buy
radium for the Radium Institute in Warsaw. Both decisions
were examples of her engagement in charity work.
In 1922 she was appointed member of the International
Commission on Intellectual Co-operation by the Council of
the League of Nations. Without regretting her early attitude
to resist patenting her own ideas, she became an advocate of
scientists’ right to patent their discoveries and inventions. She
also campaigned for free access to international scientific lit-
erature, for internationally recognized scientific symbols and
standards and for free international exchange of scientists.
In spite of her commitment to France, Marie Curie always
maintained close contact with her native country. Due to her
generosity and initiative, the Radium Institute in Warsaw was
founded in 1932, with its foremost task of utilizing the heal-
ing properties of radium to protect health and save human
lives. Marie Sklodowska-Curie died on 4 July 1934 of leukemia
caused by prolonged exposure to radioactive substances.
Under Maria Sklodowska-Curie’s guidance, about 483 sci-
entific publications were published, and 34 doctorates were
awarded. The Institute of Radium provided treatment with
radium to about 8000 patients. She was widely acclaimed for
her scientific achievements and granted numerous awards
and distinctions, honorary degrees from many  universities
and honorary memberships of learned societies. Apart from
scientific achievements, she was a happy mother of two
daughters; Irene and Eve.
In Marie Curie’s time, first cancers treated using radium
were easily accessible surface and body cavity tumors. Of the
latter, cancer of the cervix was the most frequently treated.
In the mid-1930s, cancers in many  sites were considered to
be incurable. But with time the situation changed, owing to,
among others, many  female scientists faithful to Marie Curie’s
idea of fight against cancer. Their achievements increased
the understanding of cell-killing mechanisms, normal tissue
toxicity, effect of dose fractionation and tumor biology and
influenced progress in RT. Many of them shared some ele-
ments of Marie’s biography, including, emigration to a foreignto work, strong family values, and scientific collaboration with
their husbands. The best examples could be the cooperation
of Tikvah Alper with Michael Sterne, Juliana Denekamp with
d radiotherapy 2 1 ( 2 0 1 6 ) 250–258
Fig. 1 – Tikvah Alper (first from right) with Juliana
Denekamp and Jack Fowler at the Gray Laboratory (about252  reports of practical oncology an
Bo Littbrand, Fiona Stewart with Adrian Begg, Peggy Olive with
Ralph Durand or Carmel Mothersill with Colin Seymour.
Because of space limit, I will concentrate on their main
achievements, omitting their honorable awards and positions,
distinctions, books and hundreds of publications.
This subjective review starts with Alma Howard
(1913–1984), a pioneer of cell cycle studies, who worked
in the early 1950s at Hammersmith Hospital in London. She
(with Stephen Pelc) was the first to explore and describe the
cell cycle in eukaryotic cells.4 Using radioactive tracers (the
technique which revolutionized the field of cell biology), they
found that, unlike bacteria, eucariotic cells synthesized DNA
only in S-phase rather than continually through interphase.
The definition of cell phases: G1, S, G2 and mitosis formed the
basis for the modern studies of growth control in molecular
biology and biomedicine.
One of the pioneers of British radiobiology was Tikvah Alper
(1909–1995) who  had a great influence on several generations
of radiobiologists, not only in Britain but internationally. In the
early 1950s, she worked on target theory at the Experimen-
tal Radiopathology Research Unit at Hammersmith Hospital
in London. Radiobiology then became heavily concentrated
on cell survival curves, based on target theory, which were
described by mean lethal dose (Do) and hit number. If was
found that hit numbers for different cell lines in vitro spread
from 1.0 to many  hundreds, Tikvah Alper changed their name
from ‘hit number’ to extrapolation number.5,6 She was inter-
ested also in oxygen effect, Relative Biological Effectiveness
(RBE) of fast neutrons and transmissible (neither a virus
nor a bacterium) agent in scrapie and BSE (bovine spongi-
form encephalopathy).7 She was the first to recognize, by
UV absorption studies, that the infectious agents (prions),
which include scrapie and BSE, also known as “mad cow dis-
ease” in cattle (and Creutzfeldt-Jakob disease in humans),
are not replicated or transmitted as nucleic acid nor pro-
teins (epidemic first diagnosed in 1986 in Great Britain). Prions
are infectious agents composed of protein in a misfolded
form. This is in contrast to all other known infectious agents
(virus/bacteria/fungus/parasite) which must contain nucleic
acids (either DNA, RNA, or both). The word prion is derived
from the words protein and infection.
In the 1950s, Tikvah Alper suggested that membranes
may constitute another (apart from DNA) important radia-
tion target in cells. This has led to attempts at explaining the
involvement of membrane lesions in cell killing (apoptosis)
and in promoting radiation resistance.8
She was born in South Africa and married to a bacteriol-
ogist (Michael Sterne). At that time, it was impossible for a
married woman to obtain a good scientific post in South Africa
so she devoted herself to her family. Nevertheless, she also
worked together with her husband, in a small private labora-
tory in the garden of their home. Later, she became employed
as head of the Biophysics Section of National Physics Labora-
tory but in 1951 when she lost her position, she came to Great
Britain and joined the group of scientists working at Hammer-
smith Hospital with Hal Gray.9 In 1962, she was appointed
director of the unit. Tikvah Alper was an outstanding radio-
biologist who had to overcome many  obstacles in her private
and professional life. Alper was a lifelong feminist. She was
happily married for 62 years but never changed her name and1970), (Jack Fowler courtesy).
never wore a wedding ring.9 She was a skillful educator of deaf
children (her oldest son was born deaf). She was an important
role model for many  women, showing them that they could
succeed in a very demanding career without having to sacrifice
family values and that the gender of scientists was irrelevant.
She opposed the common social practice of giving little public
recognition to women.
Under Tikvah Alper’s direction, the Experimental
Radiopathology Research Unit at Hammersmith became
one of the world’s leading radiobiology centers. After her
retirement in 1973, she worked as a senior advisor at the
Gray Laboratory from 1974 until 1977 (Fig. 1). Tikvah Alper
cooperated with Shirley Hornsey who was a very productive
scientist working on radiation injury in mouse lung,10 spinal
cord,11 jejunum,12 RBE of fast neutrons,13 and hypoxia. Her
most remarkable achievement was obtained in cooperation
with Hal Gray. She was involved in studies showing the rela-
tionship between oxygen tension and radiosensitivity, using
mouse and chicken cells. She studied the effect of oxygen on
tumor response to irradiation. Hornsey is the co-author of
the widely known paper by Hal Gray14 reporting that oxygen
might sensitize a tumor to X-rays more  than normal tissues.
The authors of the study were the first to suggest the use
of oxygen to improve the therapeutic index of radiotherapy.
Hal Gray later moved from the Hammersmith Hospital to the
Mount Vernon Hospital and the Gray Laboratory.
In 1968, Juliana Denekamp (1943–2001) was employed in
the same center. She quickly became a distinguished English
radiobiologist. Between 1988 and 1994, Juliana Denekamp
was director of the Gray Laboratory, UK. Thereafter, she was
appointed Professor of Translational Research at the Umea
University, Sweden, where she moved to join her husband,
radiation oncologist Bo Littbrand. They worked in close coop-
eration. She was very active there, both as a researcher and
teacher, until her early death in June 2001. Juliana Denekamp
was a leading international scientist in radiation biology
applied to radiotherapy and well known and admired for her
habit of asking penetrating questions at meetings.
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Fig. 2 – Graph presenting the difference between biological
data (full curve) measured experimentally for the first time
by J. Denekamp in mouse skin16 and Nominal Standard


































Fig. 3 – Juliana Denekamp and Elizabeth Travis in Los
Angeles at their leisure time (Jack Fowler courtesy).Juliana Denekamp was recognized for significant contrib-
tions to dozens of topics in radiobiology applied to radiation
ncology. She authored about 300 publications,15 therefore,
nly some of which are highlighted.
In 1973 Denekamp showed, for the first time experimen-
ally, that the time factor for acute reactions in mouse skin
onsisted of a delay of one or two population turnover times
ollowed by a rapid increase in the dose required to keep the
iological effect constant. This increase was, as she showed,
ssociated with higher proliferation rate in the basal layer
f the skin.16 The time-course was exactly the opposite of
he then accepted model of Nominal Standard Dose (NSD)
nd Time-Dose Factor (TDF), which provided for the biologi-
al effect to be large at first and then decreasing (Fig. 2). The
ifference between biological data measured experimentally
nd NSD and TDF theoretical curve was shown, for the first
ime, for acute reactions in mouse skin.16,17
Denekamp examined cell kinetics in mouse tumor and the
elationship between reoxygenation and cell loss rate. She
ointed out greater cell loss factors (faster shrinkage following
rradiation) in carcinomas than in sarcomas.18
She studied radioprotectors, like WR2721 (Amifostine)
nd showed radioprotection of WR-2721 in all the tumors
ested, as well as in normal tissues.19,20 Denekamp showed
lso much faster proliferation of endothelial cells in tumors
han in normal tissues (except in wound-healing and fetal
evelopment).21
Denekamp made major contributions in designing radio-
herapy schedules: CHART (Continuous hyperfractionated
ccelerated radiotherapy) and ARCON (Accelerated Radiothe-
apy with Carbogen and Nicotinamide). The CHART schedule,
elivering a dose exceeding 50 Gy, with 3 F a day of 1.5 Gy (36
) in 12 treatment days – without a weekend gap – was devel-
ped with Stanley Dische, Michele Saunders and Jack Fowler
t the Mount Vernon Cancer Centre.22 ARCON was studied in
everal trials and has recently been shown to improve regional
ontrol in laryngeal tumors.Julie Denekamp was involved in research methodology. She
designed the “top-up” technique for investigating effects of
many small fractions of X-rays and neutrons.
She led a major program of development in the Gray Lab
of new techniques to investigate late complications in mice,
with functional tests that did not require the sacrifice of the
animal. Results could be obtained for a sequence of times after
irradiation in the same animals. Techniques were developed
to irradiate small, well-defined, regions of the mouse and to
measure progressive functional damage in the lung (breath-
ing rate and lethal pneumonitis),23 bladder (urinary frequency,
bladder contraction),24,25 and rectum (short feces).26,27 The
results clarified and underpinned the clear difference in /
ratios between early and late-responding tissues described by
Thames et al.,28 in the same period.
The American radiobiologist Elizabeth L. Travis from MD
Anderson Cancer Center spent 3 years at the Gray Lab in the
late 1970s. Having special pathology knowledge about radia-
tion damage to the lungs, she made a great input to research
on radiation induced normal tissue damage. Late effects that
develop in normal tissues adjacent to the tumor site in months
to years after therapy can reduce the quality of life in can-
cer survivors. Working in the Gray Laboratory between 1976
and 1979, together with Juliana Denekamp, she introduced to
experimental radiobiology non-harmful assays performed on
living animals (Fig. 3). The end-point was breathing rate which
was measured simply by the frequency of pressure changes in
a mouse spirometer, for each mouse on each experimental
day after irradiation.23,29,30 Later, she looked at molecular sus-
ceptibility to radiation induced pulmonary fibrosis.31,32 The
now well known contrasts between the early and late types
of radiation injury were then identified and investigated, and
found indeed to mirror the early pneumonitis and later fibro-
sis occurring in human lungs. The studies are so important,
because late effects that develop in normal tissues adjacent
to the tumor site in months to years after radiotherapy can
reduce the quality of life in cancer survivors.
Elizabeth Travis stays faithful to the ideas of Marie Curie.
She is a strong advocate for the advancement of women in
academic medicine, both at MD. Anderson and nationally.
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Fig. 4 – Fiona Stewart (first from right) during discussion
with Anamaria Rojas and Elizabeth Travis at one of the
conferences (Jack Fowler courtesy).
Fig. 5 – Andree Dutreix (second from left) with Joseph
Rotblat (Nobel Peace Prize Laureate in 1995), Juliana
Denekamp and the author during barbecue at Marie Curie
Symposium in Umea (Sweden, June 1998), (Author’s
archive).
Trust in Manchester. She used a clonogenic assay (consideredOver her career as a professor, she was the Vice President
of Women Faculty Programs, the Provost’s Office, the Uni-
versity of Texas MD  Anderson Cancer Center, Houston, TX.
Elizabeth Travis established and secured an endowment for
the Margaret L. Kripke Legend Award for promotion of women
in cancer medicine and cancer science. In 2009 she obtained
an AAMC Women in Medicine Leadership Development Award
(Association of American Medical Colleges).
Fiona Stewart, professor of radiobiology in the Division
of Experimental Therapy, the Netherlands Cancer Institute,
Amsterdam, developed a reputation for her studies on nor-
mal  tissue damage and the radiobiology of both acute and
late complications.24,25 Whilst working in the Gray Laboratory
with Juliana Denekamp (till 1984) she showed, using labeled
cell autoradiography, that the natural pre-irradiation turnover
time (Tpotential doubling time) of a normal tissue deter-
mines whether radiation damage in an organ occurs early or
late.33 Late responding normal tissues were shown to behave
differently from tumors and acutely responding normal tis-
sues to fractionated radiotherapy, which had profound clinical
implications (Fig. 4). She also studied hypoxic-cell radiosen-
sitizers, and capillary-damaging agents in tumors (including
interactions between radio-protecting compounds and light-
sensitization compounds for therapy and other interactions
of chemotherapy and radiotherapy).
After moving to Amsterdam (1984), she continued to inves-
tigate mechanisms of late radiation injury, particularly the
long term recovery potential of tissues and their tolerance
to re-irradiation.34,35 She studied the link between functional
damage and vascular mediated inflammatory and thrombotic
changes.36 One of her big interests is photodynamic therapy in
oncology. During the 1990s, Fiona Stewart set up a pre-clinical
program to investigate the potential of photodynamic therapy
(PDT) for the treatment of small superficial tumors. Her work
demonstrated that vascular mediated damage is an essential
component to curative PDT and this knowledge had a major
influence on the design of optimal clinical schedules.Fiona Stewart received the 2012 Weiss Medal (Association
for Radiation Research), the 2014 ESTRO Lifetime Achievement
Award, the 2014 Bacq & Alexander Award (European Radiation
Research Society), and the 2015 Gray Medal (ICRU).
Andree Dutreix from the Institute of Gustave-Roussy,
Villejuive, France, is a medical physicist. She developed
standards for quality assurance in brachytherapy and tele-
radiotherapy.37,38 A. Dutreix was involved in development
of the European Quality Assurance Network for external
RT based on thermoluminescent dosimetry.39 In the early
1980s she worked on the RBE of neutrons, helium ions and
Californium-251 (Fig. 5).
Since the early 1980s, clinical studies have shown that
patients with the same tumor types and treated according to
the same RT schedule have different tumor responses and dif-
ferent degrees of normal tissue damage. It became obvious
that the variation in RT responses may depend on biological
factors. Knowledge of these parameters could provide clini-
cians with relevant information needed to select appropriate
treatments, and this has led to the search for predictive assays.
There are three important radiobiological factors involved
in determining tumor response to radiotherapy: proliferation,
hypoxia and cellular radiosensitivity. In terms of radiosensi-
tivity, there is general agreement that not only tumors, but
also normal individuals differ in their intrinsic radiosensiti-
vity. Pretreatment assessment of the parameter has potential
for use by clinicians to allow dose or treatment modifications.
The inherent radiosensitivity of a cell has been defined by
many different factors. In vitro studies suggest that three fac-
tors produce most of the variations seen in tumor cells: DNA
repair, cell growth characteristics, and genome instability.
The largest study looking at tumor cellular radiosensitivity
in relation to RT outcome was carried out by Catharine West
from the Institute of Cancer Sciences, Christie Hospital NHSthe gold standard method) to examine radiosensitivity of cells
derived from primary tumor biopsies. Radiosensitivity was
reports of practical oncology and radio
Fig. 6 – Catharine West, the author and Peggy Olive at the






































ages that lead to a greater proportion of nonreparable DNArchive).
easured as a surviving fraction after 2 Gy in vitro irradiation
SF2). The test was suggested as a predictive assay.40
Her work showed that in vitro measurement of tumor cell
adiosensitivity is a highly significant prognostic factor for
arcinoma of the cervix treated with radiotherapy41 (Fig. 6).
he examined also other methods (chromosomal aberrations)
nd other biological parameters (hypoxia) in human tumors.42
est established the Translational Radiobiology Group with
he aim to characterize molecular patient profiles that reflect
elevant biological phenotypes and predict tumor and normal
issue response to radiation. She uses assays carried out in
arious clinical samples at the DNA (genome), RNA (trans-
riptome) or protein (proteome) level.43 At present, she is
nterested in the genome-wide association study for identifi-
ation genes of late RT toxicity.44 This is an important problem
s late toxicity in RT can limit treatment intensity, thus pre-
enting increase in dosage and lowering the probability of
umor control.
Peggy Olive from the British Columbia Cancer Research
entre in Canada developed a method to measure DNA
amage in individual cells based on the technique of
icroelectrophoresis.45 Cells embedded in agarose are lysed,
ubjected briefly to an electric field, stained with a fluorescent
NA-binding stain, and viewed using a fluorescence micro-
cope. Broken DNA migrates farther in the electric field and
he cell then resembles a “comet” with a brightly fluorescent
ead and a tail region which increases as damage grows.
This method became popular after its usefulness had been
roved in some clinical studies. This method has been used
or measuring DNA damage, hypoxia and apoptosis.45,46 Peggy
live used also H2AX foci as the method for indication of
ethal DNA damage.47,48 She also studied the expression of
ndogenous hypoxia markers (HIF-1, CAIX) and application of
imonidazole and Eppendorf electrode in human tumors.
Ingela Turesson, Professor of Radiation Oncology from
he Department of Radiology, Oncology and Radiation Sci-
nce, Uppsala, Sweden, has significant achievements in
ssessing intrinsic radiosensitivity in a clinical setting. She
ooked for correlation between in vitro cellular radiosensiti-
ity with in vivo normal-tissue responses. She also performedtherapy 2 1 ( 2 0 1 6 ) 250–258 255
prospective clinical fractionation studies on acute and late
reactions in the skin of breast cancer patients.
Turesson studied the phenomenon of HRS/IRR and indi-
cated high sensitivity in the radiation survival response of
mammalian cells at doses below <0.5 Gy. This phenomenon,
which has been termed hyperradiosensitivity (HRS), precedes
the occurrence of a relative resistance (per unit dose) to
cell killing by radiation over the dose range 0.5–1 Gy. The
latter phenomenon has been named increased radioresis-
tance (IRR).49 In the late 1980s, Ingela Turesson & Howard
Thames from the MD Anderson Cancer Center examined the
repair capacity and kinetics of human skin during fraction-
ated radiotherapy. Endpoints were: erythema, desquamation,
and telangiectasia after 3 and 5 years’ follow up.50 The authors
found 2 values of repair half time (T1/2) in human skin: there
was a fast repair component of 0.3–0.4 h and slower compo-
nents of 1.1–1.3 for acute effects and 3.5 h for late effects.
Since then, 6 h or longer intervals between fractions are rec-
ommended in radiotherapy schedules.51 Recently, she became
involved in studies of proton therapy.52
Irena Szumiel from the Institute of Nuclear Chemistry and
Technology in Warsaw is interested in the monitoring and
signaling of radiation-induced damage in mammalian cells.
Her main interests cover factors determining mammalian cell
sensitivity to ionizing radiation in a model of mouse leukemia
L5178Y (LY)-consisting of 2 sublines differing in susceptibil-
ity to cytotoxic agents and DNA repair.53,54 She studies DNA
repair, cell signaling, and radiosensitivity markers. Irena Szu-
miel has authored a number of reviews on the subject.55–57
Penny Jeggo from the University of Sussex, Brighton,
England, studies mechanisms of DNA double-strand breaks
(DSBs) repair in mammalian cells.58,59 She is especially inter-
ested in DNA non-homologous end-joining (NHEJ), a major
DSB repair pathway in mammalian cells.60 She works on the
identification of genes involved in this process and looks for
proteins interacting with the well characterized components
of the DSB repair machinery.61 Her recent work concerns
differences in repair of DSBs localized in eu- and heterochro-
matin, which has highlighted how chromatin complexity
influences not only the factors required for DSB repair but
also the pathway choice. Understanding the consequences of
defects in DSB repair mechanisms for the cellular response
to ionizing radiation may contribute to improvements of
radiotherapy.62
High-LET irradiation is recommended for radioresistant
tumors. For these new particles, heavy-ion radiobiology is
needed. A representative of this field is Eleanor Blakely, a
biophysicist from Ernest Orlando Lawrence Berkeley National
Laboratory, California. She has studied the mechanisms
underlying the increased biological effectiveness of densely
ionizing radiations, including alpha particles, neutrons and
highly energetic heavy charged particles.63 She examined
DSBs, their repair, induction of chromosomal aberrations in
mammalian cells after irradiation with heavy-ion beams. She
showed that the increased biological effectiveness of densely
ionizing radiations may be a result of clustered DNA dam-strand breaks, compared to sparsely ionizing radiation.64,65
Recently, (July 2014) in CERN, she presented a seminar on “60
years of particle therapy” showing the efforts of CERN and
d rad
r
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the Lawrence Berkely National Laboratory in developing treat-
ment for cancers with protons and carbon. Eleonor Blakeley
serves also as consultant in support of clinical radiotherapy
trials, and of issues pertinent to radiation protection.
In the USA, Maria Curie’s ideas were developed by Helen
Evans (1924–2007), Professor of Radiation Oncology, University
of Wisconsin. Her work was focused on molecular and cellu-
lar consequences of exposure to ionizing radiation. She was
a pioneer in elucidating the mechanisms of ionizing radia-
tion mutagenesis in mammalian cells and the induction of
genomic instability (some have even referred to her as the
Mother of Mutagenesis).66,67 She worked with a wide range
of biological systems (viruses, bacteria, slime molds, rodents).
Definition of mutagenesis given by Evans: genomic insta-
bility can be initiated by complex, poorly repaired DNA
damage induced by low doses of ionizing radiation that leads
to a mutator phenotype.68 She was also interested in photody-
namic therapy (PDT). The technique is used clinically to treat
malignant tumors and is considered as both minimally inva-
sive and minimally toxic. Most modern PDT involves three
key components, a photosensitizer, a light source and tissue
oxygen.69 Hellen Evans was active in many  professional soci-
eties and her favorite was the Radiation Research Society of
which she was the President between 1994 and 1995.
At present, we  know that microenvironment plays a signif-
icant role in tumor development and growth and is considered
a target in tumor response to radiotherapy. Great achieve-
ments in this field and understanding of the biology of solid
tumors and improvement in cancer treatment were obtained
by Sara Rockwell, professor of Therapeutic Radiology and
Pharmacology at Yale School of Medicine in Boston. Her
work is focused on studying the unphysiological microenvi-
ronments of cells within solid tumors, its influence on the
biology of tumor cells and of the stromal elements within solid
tumors.70 She showed that the microenvironmental inade-
quacies within solid tumors alter the proliferation patterns of
the cells, the metabolic pathways used by the cells, the ability
of the cells to tolerate stress, DNA damage, and other injuries,
and the response of the cells to radiation and antineoplastic
drugs.71,72 Rockwell studies their implication on the devel-
opment and progression of solid tumors. She is involved in
developing therapeutic strategies to improve cancer therapy.
Sara Rockwell is also the author of a review on the evolution
of experimental radiotherapy over the past century.73
The old way of thinking about the pathophysiology of nor-
mal  tissue effects has changed in the last years because of
our better understanding of radiation injury mechanisms at
the molecular level. At present, it is believed that normal tis-
sue response to radiation is an integrated response involving
cell death (target cell theory) and the production of cytokines,
reactive oxygen species and alterations in gene expression of
many cells. Apart of direct, cytocidal effects, radiation can
produce indirect and functional effects. Examples of indi-
rect effects are the bystander effect and the secretion of
pro-inflammatory cytokines that can induce an inflammatory
response.Carmel Mothersill, an Irish radiobiologist (McMaster Uni-
versity, Ontario, Canada), is famous for pivotal studies on
radiation-induced bystander effect (RIBE). This is the phe-
nomenon in which unirradiated cells exhibit irradiationiotherapy 2 1 ( 2 0 1 6 ) 250–258
effects as a result of signals received from nearby irradiated
cells. This phenomenon contradicts the old radiobiological
dogma that the damage effects of radiation are the results
of direct ionization of cell structures, particularly DNA.  Prof.
Carmel Mothersill showed that the RIBE is induced by agents
and signals emitted by directly irradiated cells and manifests
as lowering of survival, cytogenetic damage, apoptosis and
biochemical changes in neighboring non-irradiated cells.74,75
The bystander effect can be induced by radiation doses as low
as 2 mGy; however, ‘low dose’ in RT means generally less than
0.5 Gy. Carmel Mothersill has shown that low dose effects are
complex and induce, among others, apart from RIBE, genomic
instability (commonly described as a non-targeted effect).76
Recently, Carmel Mothersill’s research has moved from in vitro
to in vivo studies using fish species and mammals and provides
results for the general discussion on radiation protection.77
In the times of Marie Sklodowska-Curie, she was virtu-
ally the only woman recognized as a great scientist among
many men. The ladies presented in the article also functioned
among numerous male scientists involved in radiobiology.
Although they constituted less than 40% of the community,
they made significant contribution to the development of
radiotherapy and more  efficient cancer treatment. Due  to their
studies, new schedules of RT and new types of ionizing radi-
ation have been applied, lowering the incidence of normal
tissue toxicity. Their achievements herald the future of per-
sonalized RT.





The author would like to thank Prof. Jack Fowler for all the
information, photographs and for his being so helpful, encour-
aging and enthusiastic towards all women scientists who
cooperated with him.
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